Life Sciences QMS: Quality Management for Biotech, Pharma, and Research

One platform across every life sciences vertical.

Life Sciences QMS Software: One Configurable Platform for Pharma, Biotech, CRO, and CDMO Quality Systems

Life sciences is not a synonym for pharmaceutical manufacturing. The term covers a range of organisations with materially different regulatory obligations, operational models, and QMS requirements. A pharmaceutical manufacturer running commercial drug production under 21 CFR Part 211 operates a fundamentally different quality system from a biotechnology company managing Phase II clinical trial documentation under ICH E6, a contract research organisation maintaining study-specific records for multiple sponsors simultaneously, or a contract development and manufacturing organisation running separate quality programs for pharmaceutical and biologic clients under one roof.

The QMS platforms that dominate life sciences marketing — Greenlight Guru for medical devices, Qualio for early-stage pharma, MasterControl for regulated document management — each serve a specific sub-vertical with depth but limited breadth. DotCompliance and Scilife hold some life sciences keyword positions, but without the functional depth that a CRO managing multi-sponsor audits or a CDMO balancing pharmaceutical and biologic quality programs actually requires.

eLeaP’s life sciences QMS software is configurable across the full range of life sciences verticals. This page covers what each vertical requires, how the ICH quality framework governs the sector, and where eLeaP’s configurable architecture addresses requirements that sub-vertical tools cannot.

The Life Sciences QMS Landscape: Six Verticals, Six Sets of Requirements

Naming the verticals and their distinct requirements is a prerequisite to evaluating whether a QMS platform is genuinely suited to the sector or is applying a pharmaceutical manufacturing framework to a broader label.

Pharmaceutical Manufacturers

Commercial pharmaceutical manufacturers operate under 21 CFR Part 211 in the US, EU GMP in Europe, and ICH Q10 as the international quality system standard. Their QMS requirements centre on batch production records, deviation management, OOS investigation, equipment qualification, process validation, and CAPA with effectiveness verification. Training must connect to current procedure versions and be demonstrable to FDA investigators on demand. The pharmaceutical manufacturing QMS is the most documentation-intensive in the life sciences sector.

Biotechnology Companies

Biotech companies span a wide operational range — from early-stage research organisations running Phase I trials to commercial biologics manufacturers operating under 21 CFR Part 600 series regulations for biological products. Pre-commercial biotech companies need QMS elements that manufacturing-oriented platforms do not address: protocol deviation management, investigator site training records, study-specific document control, and regulatory submission document management. The QMS at this stage supports clinical development operations rather than production floor management.

Contract Research Organisations

CROs conducting clinical trials under ICH E6 Good Clinical Practice must maintain separate quality records for each sponsor’s studies. SOPs may differ by sponsor. Training records must be study-specific. Audit access must be controlled so that Sponsor A’s quality team can review records relevant to their study without accessing Sponsor B’s data. The CRO QMS is structurally a multi-tenant quality system, and a platform that does not support that architecture forces workarounds that create audit risk.

Contract Development and Manufacturing Organisations

CDMOs face the most complex quality system architecture in the sector. A CDMO producing pharmaceutical drug products for one client and biological drug substances for another must satisfy both 21 CFR Part 211 and 21 CFR Part 600 requirements, potentially from the same facility. Client-specific SOPs, separate batch record templates by product, and quality agreements with each client that define the respective quality responsibilities all require a QMS that can segment and configure by client program without requiring separate validated system instances.

Clinical Trial Sponsors

Sponsor organisations managing Investigational New Drug applications or marketing authorisation applications need QMS support for the regulatory submission lifecycle alongside operational quality management. Regulatory document management — IND amendments, briefing documents, responses to agency requests — requires version control, authoring workflows, and submission tracking that connects to the broader quality system. Protocol amendments generate deviation management obligations at investigator sites that the sponsor QMS must capture and track.

Research Institutions

Academic and government research institutions operating under Good Laboratory Practice regulations — 21 CFR Part 58 in the US, OECD GLP principles internationally — need QMS infrastructure for study protocol management, equipment calibration records, raw data integrity controls, and personnel training documentation. GLP compliance requires that the quality assurance unit maintain independence from study operations while having access to all study records, a requirement that maps directly to eLeaP’s role-based access configuration.

The ICH Quality Framework: Q8 Through Q11 and What They Require from a Life Sciences QMS

The International Council for Harmonisation quality guidelines form the primary international framework governing quality across the life sciences sector. Understanding the ICH quality suite as an integrated framework — rather than as individual guidelines — clarifies what a life sciences QMS must support.

ICH Q8 covers pharmaceutical development, defining the principles for building quality into the product and process during development. The Quality by Design concepts in ICH Q8 — design space, control strategy, and process analytical technology — require that development-phase quality decisions are documented in a way that supports both regulatory submission and commercial manufacturing technology transfer. A QMS supporting ICH Q8 must manage development documentation with the traceability needed to support regulatory submissions while connecting development records to the commercial manufacturing quality system.

ICH Q9 covers quality risk management, establishing the principles and tools for identifying, assessing, controlling, communicating, and reviewing risks to product quality. ICH Q9 does not mandate specific risk assessment tools but requires that risk management decisions be documented and linked to the quality events — deviations, change controls, CAPA, supplier qualifications — that triggered the risk assessment. A QMS that supports ICH Q9 connects risk assessments to the quality records they inform rather than maintaining them as standalone documents.

ICH Q10 covers the pharmaceutical quality system, defining the four principal elements — knowledge management, quality risk management, CAPA, and change management — that constitute an effective quality system across the product lifecycle. ICH Q10 applies from development through discontinuation and requires that the quality system support the organisation’s objectives at each lifecycle stage. A QMS built for ICH Q10 must be configurable to the organisation’s current lifecycle stage rather than fixed to a single phase.

ICH Q11 covers the development and manufacture of drug substances, extending the Quality by Design principles of ICH Q8 to the active pharmaceutical ingredient manufacturing process. ICH Q11 requires that the development history of the manufacturing process — including process understanding data, development reports, and comparability protocols for process changes — be maintained and connected to the commercial manufacturing quality system. For organisations that both develop and manufacture, the QMS must bridge the development-phase records of ICH Q11 and the commercial manufacturing records of ICH Q10 without a documentation gap.

eLeaP’s life sciences QMS software supports the ICH quality framework as an integrated architecture. Risk assessments connect to the quality records they inform. CAPA records connect to the deviations, change controls, and audit findings that originate from them. Development documentation connects to commercial manufacturing records through the technology transfer module. The ICH framework is not a compliance checklist applied after the fact — it is the logic embedded in how records relate to each other in the system.

Biotech-Specific QMS Requirements: Clinical Development Operations Beyond Manufacturing

Biotechnology companies in Phase I through Phase III clinical development have quality system needs that manufacturing-oriented QMS platforms handle poorly or not at all. The operational centre of gravity in pre-commercial biotech is the clinical program, not the production floor. The QMS must support clinical operations quality with the same rigour that a manufacturing QMS applies to production controls.

Protocol Deviation Management

ICH E6 Good Clinical Practice requires that protocol deviations be identified, documented, reported to the sponsor, and assessed for impact on subject safety and data integrity. Each deviation requires a determination of whether it is minor, major, or an important protocol deviation requiring IRB or ethics committee notification. Deviation trends across investigator sites indicate systemic protocol execution issues that require corrective action at the site or protocol level. eLeaP’s deviation management workflow is configured for clinical protocol deviations with the GCP-specific categorisation, impact assessment, and reporting workflow that clinical operations quality requires.

Investigator Site Training Records

GCP requires that all personnel involved in conducting a clinical trial be qualified by education, training, and experience to perform their respective tasks. The sponsor is responsible for ensuring that investigator site staff are trained on the protocol, the investigational product, and applicable GCP requirements. Training records for site personnel must be maintained by the sponsor or CRO and must be available for regulatory inspection. eLeaP’s training matrix manages site-specific training requirements by study and site, with completion records traceable to the protocol version and the investigational product information version that were current at the time of training.

Study-Specific Document Control

Clinical trial documentation — protocols, informed consent forms, investigator brochures, pharmacy manuals, and laboratory manuals — requires version control, site-specific distribution management, and a record of which version each site was operating under at each point in the trial. When a protocol is amended, the amendment must be distributed to all active sites, the site’s IRB or ethics committee must approve the amended protocol before implementation, and the training records must reflect that site personnel were trained on the amendment before enrolling subjects under the new protocol version. eLeaP’s document control module manages clinical document distribution with site-level tracking of version acknowledgment and training completion.

Regulatory Submission Document Management

IND applications, NDA submissions, BLA submissions, and their amendments require document management that connects regulatory submissions to the underlying quality system records that support them. A chemistry, manufacturing, and controls section of an NDA references the process validation data, the analytical method validation records, and the stability data that are maintained as quality records in the QMS. When a regulatory agency issues a complete response letter requesting additional information, the response must draw on quality records that are traceable, current, and accessible. eLeaP manages regulatory submission documents within the same document control architecture as quality system procedures, with version history and the record connections that support regulatory responses.

CDMO and CRO Quality Systems: Multi-Sponsor Architecture and Client Audit Management

Contract manufacturers and research organisations face a quality system challenge that no single-client organisation encounters: multiple clients, multiple sets of quality requirements, multiple quality agreements, and multiple potential audit events — sometimes simultaneously. The QMS must support multi-sponsor operations without requiring separate validated system instances for each client and without allowing one client’s quality data to be accessible to another.

eLeaP’s configurable access architecture addresses this directly. Role-based access controls scope each client’s quality representatives to the records and documentation relevant to their programs. A pharmaceutical client’s quality team can access the batch records, deviation records, and CAPA records associated with their product without accessing records from a separate biologic client’s program operating in the same facility. Client audit access is configured at the record level, not at the system level — the CDMO does not need to create a separate environment for each client audit.

SOPs and work instructions that differ by client program are configured within the same document control system with program-level tagging. A manufacturing procedure that applies only to Client A’s product does not appear in the document set visible to Client B’s quality team. When a client’s SOP is revised, the retraining assignment is generated only for the personnel roles associated with that client’s production activities, not for the broader production workforce. Training matrices are configured by client program, so a CDMO with six active client programs maintains six distinct training requirement sets within a single system rather than in six separate tracking mechanisms.

Audit management for CDMOs and CROs requires that client audit findings, responses, and CAPA commitments be trackable by the client without being visible across clients. eLeaP’s audit management module supports client-specific audit records with access controls that allow the client to view their audit findings and the CDMO’s responses while the CDMO quality team maintains visibility across all client programs. Overdue CAPA responses to client audit commitments surface in the CDMO quality management dashboard before they become escalation events in the client relationship.

Integrated Training Across Life Sciences: One Requirement, Many Configurations

Training is a regulated requirement across every life sciences vertical, but the training requirement takes a different form in each. Pharmaceutical manufacturing requires training on current GMP procedures with records demonstrating procedure-version currency. Clinical development requires GCP training for all personnel involved in trial conduct, with records demonstrating study-specific qualification. CDMOs require client-specific training records that demonstrate personnel are qualified to work on each client’s product under the applicable quality agreement. Research institutions require GLP training records demonstrating qualification for specific study functions.

eLeaP’s integrated QMS and LMS handles each of these configurations from the same platform. The training matrix is configurable by role, by program, by client, and by applicable regulatory framework. A new study coordinator at a CRO receives training assignments for GCP requirements, sponsor-specific protocol training, and site-specific procedures — all generated automatically from the role assignment and study enrollment, without manual enrollment by a training administrator.

When an SOP governing a GMP process at a pharmaceutical manufacturer is revised, retraining assignments are generated automatically for affected roles. When a clinical protocol is amended at a biotech, study-specific training assignments are generated for affected site staff. When a client SOP is revised at a CDMO, retraining assignments are generated only for the personnel assigned to that client’s program. The same system logic applies across all configurations — the configuration determines the scope of each training trigger, not the underlying architecture.

For regulatory inspections and client audits, training compliance reports are a native output. The report shows, for any specified role or individual, the current required training profile, the completion status for each item, the version of the document or program each completion record references, and whether any items are overdue or approaching their retraining interval. This report generates in seconds and covers both QMS and training data in a single view, without manual reconciliation across separate systems.

Evaluating Life Sciences QMS Software: Questions That Expose Sub-Vertical Limitations

Most QMS platforms marketed to life sciences organisations are purpose-built for one vertical and extended to others through marketing rather than product development. The questions below expose those limitations.

eLeaP’s answers to all five questions are yes, demonstrable in a scoped walkthrough configured for the buyer’s specific vertical. Whether the evaluation is for a pharmaceutical manufacturer, a biotech in Phase III, a CRO managing multi-sponsor audits, or a CDMO balancing pharmaceutical and biologic programs, the demo covers the workflows specific to that environment. Request a scoped life sciences demo at eleapsoftware.com.

Related resources: